Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients

NCT00333060 is registered in ClinicalTrials.gov with Othera Pharmaceuticals as lead sponsor.

NCT NCT00333060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00333060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients
Lead sponsor
Othera Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2005
Completion date
January 31, 2008
Enrollment
164 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

epiretinal membrane, macular hole